{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:28:58Z","timestamp":1761560938240,"version":"3.40.3"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3895,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>New drugs and advances in molecular biology afford opportunities to upgrade the treatment of autoimmune hepatitis. The aims of this study were to define treatment problems, identify possible solutions, and stimulate investigations to improve patient care. A clinical subcommittee of the International Autoimmune Hepatitis Group reviewed current management difficulties and proposed corrective actions. The assessment of new front-line and salvage therapies for adults and children were given top priority. Cyclosporine and mycophenolate mofetil were endorsed as drugs worthy of rigorous study in severe disease, and budesonide was endorsed for study as front-line therapy in mild disease. Diagnostic criteria and treatment regimens for children required codification, and pharmacokinetic studies were encouraged to develop optimal dosing schedules based on therapeutic ranges. Collaborative efforts were proposed to help understand racial, geographical, and genetic factors affecting outcome and to establish definitions and therapies for variant syndromes and graft dysfunction after transplantation. The development of experimental animal models was deemed essential for the study of site-specific molecular interventions, and gene therapy was endorsed as a means of bolstering reparative processes<\/jats:bold>. <jats:bold>\n                                    In conclusion,\n                                 <\/jats:bold>\n                                 <jats:bold>evolving pharmacological and technical advances promise to improve the treatment of autoimmune hepatitis, and investigations of these advances are timely, feasible, and necessary. (Hepatology 2005;41:207\u2013215.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.20539","type":"journal-article","created":{"date-parts":[[2004,12,23]],"date-time":"2004-12-23T01:17:14Z","timestamp":1103764634000},"page":"207-215","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":71,"title":["Treatment challenges and investigational opportunities in autoimmune hepatitis"],"prefix":"10.1097","volume":"41","author":[{"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco B.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herschel A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward L.","family":"Krawitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian G.","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Mieli-Vergani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gotaro","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Vergani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Zeniya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-29-20250325","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","article-title":"Diagnosis and treatment of autoimmune hepatitis.","volume":"36","author":"Czaja","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R2-29-20250325","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1089-3261(02)00029-6","article-title":"Evolving new therapies of autoimmune hepatitis.","volume":"6","author":"Vierling","year":"2002","journal-title":"Clin Liver Dis"},{"key":"R3-29-20250325","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2002-35706","article-title":"Treatment of autoimmune hepatitis.","volume":"22","author":"Czaja","year":"2002","journal-title":"Semin Liver Dis"},{"key":"R4-29-20250325","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/0016-5085(93)90656-W","article-title":"The nature and prognosis of severe cryptogenic chronic active hepatitis.","volume":"104","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"R5-29-20250325","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0168-8278(94)80251-3","article-title":"The nature and prognostic implications of autoimmune hepatitis with an acute presentation.","volume":"21","author":"Nikias","year":"1994","journal-title":"J Hepatol"},{"key":"R6-29-20250325","first-page":"138","article-title":"Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure.","volume":"11","author":"Porta","year":"1990","journal-title":"J Pediar Gastroenterol Nutr"},{"key":"R7-29-20250325","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/gast.1997.v113.pm9247489","article-title":"A novel histological lesion in glucocorticoid-responsive chronic hepatitis.","volume":"113","author":"Pratt","year":"1997","journal-title":"Gastroenterology"},{"key":"R8-29-20250325","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hep.1840020213","article-title":"Chronic lobular hepatitis: a clinicopathological and prognostic study.","volume":"2","author":"Liaw","year":"1982","journal-title":"HEPATOLOGY"},{"key":"R9-29-20250325","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/jhep.2001.27562","article-title":"Autoimmune hepatitis with incidental histologic features of bile duct injury.","volume":"34","author":"Czaja","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R10-29-20250325","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.","volume":"40","author":"Czaja","year":"2004","journal-title":"J Hepatol"},{"key":"R11-29-20250325","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.20235","article-title":"Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis.","volume":"39","author":"Czaja","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R12-29-20250325","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","article-title":"Short-term cyclosporine induces a remission of autoimmune hepatitis in children.","volume":"30","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R13-29-20250325","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-3476(99)70339-2","article-title":"Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis.","volume":"135","author":"Debray","year":"1999","journal-title":"J Pediatrics"},{"key":"R14-29-20250325","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/j.1572-0241.2001.05272.x","article-title":"Autoimmune hepatitis in African Americans: presenting features and responses to therapy.","volume":"96","author":"Lim","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R15-29-20250325","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/j.1572-0241.2002.06019.x","article-title":"Prevalence of autoimmune liver disease in Alaska natives.","volume":"97","author":"Hurlburt","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R16-29-20250325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00004836-200208000-00012","article-title":"Type 1 autoimmune hepatitis in Turkish patients: absence of association with HLA B8.","volume":"35","author":"Kosar","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"R17-29-20250325","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.50.5.713","article-title":"Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin.","volume":"50","author":"Zolfino","year":"2002","journal-title":"Gut"},{"key":"R18-29-20250325","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.510300611","article-title":"Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition.","volume":"30","author":"Pando","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R19-29-20250325","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0016-5085(92)90041-V","article-title":"HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients.","volume":"103","author":"Seki","year":"1992","journal-title":"Gastroenterology"},{"key":"R20-29-20250325","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/00007890-199560120-00013","article-title":"A randomized prospective trial of steroid withdrawal after liver transplantation.","volume":"60","author":"McDiarmid","year":"1995","journal-title":"Transplantation"},{"key":"R21-29-20250325","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00007890-198404000-00009","article-title":"Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting.","volume":"37","author":"Neuberger","year":"1984","journal-title":"Transplantation"},{"key":"R22-29-20250325","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(97)06478-7","article-title":"De-novo autoimmune hepatitis after liver transplantation.","volume":"353","author":"Kerkar","year":"1998","journal-title":"Lancet"},{"key":"R23-29-20250325","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.510280210","article-title":"Frequency and nature of the variant syndromes of autoimmune liver disease.","volume":"28","author":"Czaja","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R24-29-20250325","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1572-0241.2001.03707.x","article-title":"Understanding the pathogenesis of autoimmune hepatitis.","volume":"96","author":"Czaja","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R25-29-20250325","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","article-title":"Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.","volume":"110","author":"Roberts","year":"1996","journal-title":"Gastroenterology"},{"key":"R26-29-20250325","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004836-200207000-00016","article-title":"Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients.","volume":"35","author":"Kogan","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"R27-29-20250325","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/hep.1840060302","article-title":"The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis.","volume":"6","author":"Cooksley","year":"1986","journal-title":"HEPATOLOGY"},{"key":"R28-29-20250325","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0168-8278(92)90135-C","article-title":"Frequency of antibody to hepatitis C virus in asymptomatic HBsAg negative chronic active hepatitis.","volume":"14","author":"Czaja","year":"1992","journal-title":"J Hepatol"},{"key":"R29-29-20250325","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1440-1746.1998.tb00674.x","article-title":"Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis.","volume":"13","author":"Nakamura","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"R30-29-20250325","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hep.1840130222","article-title":"Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.","volume":"13","author":"Crosignani","year":"1991","journal-title":"HEPATOLOGY"},{"key":"R31-29-20250325","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/hep.510300603","article-title":"Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.","volume":"30","author":"Czaja","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R32-29-20250325","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","article-title":"Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis.","volume":"119","author":"Czaja","year":"2000","journal-title":"Gastroenterology"},{"key":"R33-29-20250325","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","article-title":"Oral budesonide for treatment of autoimmune chronic active hepatitis.","volume":"8","author":"Danielsson","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-29-20250325","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R35-29-20250325","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0168-8278(99)80096-8","article-title":"Behavior and significance of autoantibodies in type 1 autoimmune hepatitis.","volume":"30","author":"Czaja","year":"1999","journal-title":"J Hepatol"},{"key":"R36-29-20250325","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/08916930410001702469","article-title":"Nonstandard antibodies as prognostic markers in autoimmune hepatitis.","volume":"37","author":"Czaja","year":"2004","journal-title":"Autoimmunity"},{"key":"R37-29-20250325","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","article-title":"Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine.","volume":"33","author":"Richardson","year":"2000","journal-title":"J Hepatol"},{"key":"R38-29-20250325","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Mowat et al. Autoimmune hepatitis in childhood: a 20-year experience.","volume":"25","author":"Gregorio","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R39-29-20250325","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.2001.03782.x","article-title":"Autoimmune hepatitis in the elderly.","volume":"96","author":"Schramm","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R40-29-20250325","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0016-5085(77)80209-6","article-title":"Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.","volume":"72","author":"Schalm","year":"1977","journal-title":"Gastroenterology"},{"key":"R41-29-20250325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.2042-7158.1983.tb04255.x","article-title":"Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine in human red blood cells.","volume":"35","author":"Lennard","year":"1983","journal-title":"J Pharm Pharmacol"},{"key":"R42-29-20250325","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1572-0241.2002.05479.x","article-title":"Antibodies to soluble liver antigenliver pancreas and HLA risk factors in type 1 autoimmune hepatitis.","volume":"97","author":"Czaja","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R43-29-20250325","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","article-title":"Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.","volume":"35","author":"Ma","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R44-29-20250325","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"R45-29-20250325","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(00)00095-7","article-title":"Duration of immunosuppressive therapy in autoimmune hepatitis. letter to the editor.","volume":"34","author":"Kanzler","year":"2001","journal-title":"J Hepatol"},{"key":"R46-29-20250325","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/lt.500040313","article-title":"Allograft rejection after liver transplantation for autoimmune liver disease.","volume":"4","author":"Hayashi","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"R47-29-20250325","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/jlts.2002.32981","article-title":"Incidence and recurrence of autoimmunealloimmune hepatitis in liver transplant recipients.","volume":"8","author":"Molmenti","year":"2002","journal-title":"Liver Transplant"},{"key":"R48-29-20250325","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-3476(05)81078-9","article-title":"Incidence of cirrhosis in children with chronic hepatitis.","volume":"117","author":"Vajro","year":"1990","journal-title":"J Pediatr"},{"key":"R49-29-20250325","first-page":"20","article-title":"Recurrence of autoimmune hepatitis in children after liver transplantation.","volume":"25","author":"Birnbaum","year":"1997","journal-title":"J Pediatr Gastroenterol Nutrition"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20539","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200501000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T08:28:49Z","timestamp":1743064129000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200501000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20539","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}